A biopharmaceutical company focused on the development and commercialization of drugs to treat metabolic diseases, endocrine disorders and oncology within niche markets that have unmet medical needs.


Updates from The Motley Fool

Latest updates on Insmed from Fool.com.
Up 7%: Insmed's Data Still Mixed

Insmed  (NASDAQ: INSM) reported news regarding its treatment for resistant nontuberculous mycoba...

Insmed Prices New Stock Issue

Insmed (NASDAQ: INSM) will have nearly $60 million at its disposal if a new public stock offeri...

This Week in Biotech

With the  SPDR S&P Biotech Index  up 20% over the trailing-12-month period, it's evident that inv...

Why Insmed Shares Sank

Although we don't believe in timing the market or panicking over market movements, we do like to ...

3 Stocks to Get on Your Watchlist

I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. W...

Why Insmed Shares Soared

Although we don't believe in timing the market or panicking over market movements, we do like to ...

Insmed Earnings: An Early Look

Earnings season is winding down, with most companies already having reported their quarterly resu...

The Best of 2012: Insmed

It's the end of 2012, and that means it's time to take a look back at the year in retrospect. We'...

Top Stocks at Half-Price

You love buying your shirts when they go on sale. And who can resist a buy-one-get-one-free offer...

Why Did My Stock Just Die?

European ministers continued fixing their financial house giving encouragement to rattled markets...



Stock Performance

View Interactive INSM Charts
Sponsored by

Key Data Points

Primary metrics and data points about Insmed.
Current Price: $12.37
Prev Close: $12.48
Open: $12.45
Bid: $12.33
Ask: $12.36
Day's Range: $12.03 - $12.45
52wk Range: $9.02 - $19.30
Volume: 133,342
Avg Vol 363,720
Market Cap: $765M
P/E (ttm): -5.55
EPS (ttm): ($2.25)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Insmed.
CAPS Rating 2 out of 5
 
78 Outperform
11 Underperform
CAPS All Stars
 
14 Outperform
7 Underperform

How do you think Insmed will perform against the market?



You pick for Insmed is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Will Lewis, CEO

100% Approve

Based on 2 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Insmed.

A biopharmaceutical company focused on the development and commercialization of drugs to treat metabolic diseases, endocrine disorders and oncology within niche markets that have unmet medical needs.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers